Stryker Receives FDA Clearance for Next-Generation Ultrasonic Tissue Removal .

Stryker has received FDA 510(k) clearance for Sonopet 3, an updated ultrasonic platform designed for controlled bone and soft-tissue removal. Developed with surgeon input, the system incorporates enhanced power delivery, ergonomic improvements and Pulse Control technology to regulate tissue resection. Although primarily positioned for neurosurgical applications, ultrasonic bone removal also has relevance to technically demanding spinal procedures. Initial clinical use is expected in October, with broader commercialization planned later in 2026. Comparative evidence is needed to establish improvements in procedural safety and efficiency.